Tissue Analysis Services, Pharma Regulatory Support, Clinical Diagnostics, Diagnostic Biomarker, Drug Development, Scientists, Immuno-Oncology Drug Development, Biomarker Strategy, Companion Diagnostics, CDx, Image Analysis Technology, Global Regulatory Strategy, Accelerate Trials, Companion Diagnostic Biomarker Events Archive - Page 2 of 6 - Flagship Biosciences

2022 Upcoming Events

SITC 2021

SITC 2021 Annual Meeting: Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking

Webcast Recording: Tissue-Based CDx Development and Image Analysis in a Regulated Space

Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the

AACR Virtual Meeting 2021 – April 9-14, 2021

Flagship presented three posters at the show, including: #AACR2021 poster no. 433: Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual

Webinar: Digital Pathology with Integrated PD-L1 AI, hosted by Flagship and Gestalt Diagnostics

Join Flagship Biosciences and our partners Gestalt Diagnostics for this informative webinar featuring an overview and discussion of the value of a truly integrated,

SITC 2020

SITC 2020

SITC 2020 November 9-14, 2020 As we prepare our poster presentation for the (virtual) Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, we

Regulatory Webcast RECORDING: Biomarker Strategies and Implementation in Drug Development

READY TO TAKE THE NEXT STEP?

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.

We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.

During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.

We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.

Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.

Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.

The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.